Asenapine

CNS Drugs

Volumn 23, Issue 9, 2009, Pages 781-792

  Weber, Juliane ^a,b   McCormack, Paul L ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASENAPINE; CLOZAPINE; DOPAMINE; HALOPERIDOL; HISTAMINE RECEPTOR; IMIPRAMINE; LITHIUM; MOOD STABILIZER; NORADRENALIN; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN; VALPROIC ACID;

AGITATION; ANXIETY; AREA UNDER THE CURVE; BIPOLAR I DISORDER; BIPOLAR MANIA; BLOOD PRESSURE; CLINICAL TRIAL; CONSTIPATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEADACHE; HEART RATE; HUMAN; HYPERKINESIA; HYPERPROLACTINEMIA; INSOMNIA; LIPID METABOLISM; LONG TERM CARE; MANIA; MAXIMUM PLASMA CONCENTRATION; METABOLIC SYNDROME X; MIXED MANIA AND DEPRESSION; MORBIDITY; MUSCLE HYPERTONIA; NAUSEA; NEGATIVE SYNDROME; NONHUMAN; PARANOID SCHIZOPHRENIA; PHARMACODYNAMICS; PHYSICIAN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; QT INTERVAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; THERAPY EFFECT; TREATMENT INDICATION; VOMITING; WEIGHT GAIN; YOUNG MANIA RATING SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; SCHIZOPHRENIA;

EID: 68949207145     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11200860-000000000-00000     Document Type: Review

References (44)

1. Ayuso-Mateos JL. Global burden of bipolar disorder in the year 2000 [online]. Available from URL: http://www.who.int/healthinfo/statistics/bod- bipolar.pdf [Accessed 2009 Mar 9]
2. Ayuso-Mateos JL. Global burden of schizophrenia in the year 2000: version 1 estimates [online]. Available from URL: http://www.who.int/healthinfo/ statistics/bod-schizophrenia.pdf [Accessed 2009 Mar 9]
3. Schering-Plough Corporation. US FDA issues complete response letter for Saphris™ (asenapine) in the acute treatment of both schizophrenia and bipolar I disorder [media release]. 2009 Jan 14
4. Freedman R. The choice of antipsychotic drugs for schizophrenia. N Engl J Med 2005 Sep 22; 353 (12): 1286-8
5. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353 (12): 1209-23
6. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20 (5): 389-409
7. Revicki DA, Matza LS, Flood E, et al. Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. Pharmacoeconomics 2005; 23 (6): 583-94
8. Awad AG, Voruganti LNP. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics 2008; 26 (2): 149-62
9. Shahid M, Walker GB, Zorn SH, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009 Jan; 23 (1): 65-73
10. Tarazi FI, Moran-Gates T, Wong EH, et al. Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol. Epub 2008 Aug 21
11. HuangM, Li Z, Dai J, et al. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 2008 Nov; 33 (12): 2934-45
12. Tarazi FI, Moran-Gates T, Wong EH, et al. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl) 2008 May; 198 (1): 103-11
13. Franberg O, Wiker C, Marcus MM, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008 Feb; 196 (3): 417-29
14. Andree B, Halldin C, Vrijmoed-de Vries M, et al. Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology (Berl) 1997 Jun 11; 131: 339-45
15. 2 receptors in the rat brain. Eur Neuropsychopharmacol 2009 Mar; 19 (3): 177-87
16. Franberg O, Marcus MM, Ivanov V, et al. Asenapine elevates cortical dopamine, noradrenaline and serotonin release: evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berl) 2009 Jun; 204 (2): 251-64
17. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008; 68 (16): 2269-92
18. Potkin SG, Alva G, Panagides J, et al. Predicting clinical antipsychotic doses from preclinical and PET studies: a case study with asenapine [abstract plus poster]. American College of Neuropsychopharmacology 42nd Annual Meeting; 2003 Dec 7-11; Puerto Rico
19. Henry B, Grimwood S, de Greef HJMM, et al. Asenapine: a translational analysis of receptor occupancy in human and rat brain with therapeutic implications [abstract no. NR5-030]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC
20. Sumner BEH, Shahid M, Tarazi FI, et al. Asenapine displays distinctive induction patterns of c-fos mRNA expression in rat forebrain regions. Neuropsychopharmacology 2006 Dec; 31 Suppl. 1: 196-7
21. Tarazi FI, Choi YK, Gardner M, et al. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 2009 May; 63 (5): 413-20
22. Gerrits M, Doorstam DP, Spaans E, et al. Effect of valproate on the glucuronidation of asenapine [abstract no. PI-68]. Clin Pharmacol Ther 2008 Mar; 83 Suppl. 1: S29
23. Dogterom P, Schnabel PG, Timmer C, et al. Effect of carbamazepine on asenapine pharmacokinetics [abstract no. PII-44]. Clin Pharmacol Ther 2008 Mar; 83 Suppl. 1: S55
24. Hulskotte E, Spaans E, Timmer C, et al. Effects of water intake and smoking on the absorption of sublingually administered asenapine [abstract no. NR1-040]. 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco (CA)
25. Dogterom P, Hulskotte E, Gerrits M, et al. Asenapine pharmacokinetics: influence of cytochrome p450 modulators and udp-glucuronyltransferase inhibition [abstract no. P.3.d.008]. Eur Neuropsychopharmacol 2008 Oct; 18 Suppl. 4: S452-3
26. Peeters P, Bockbrader H, Spaans E, et al. Asenapine pharmacokinetics: influence of hepatic and renal impairment [abstract no. NR4-081]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC
27. Calabrese JR, Cohen M, Zhao J, et al. Efficacy and safety of asenapine adjunctive treatment for acute mania associated with bipolar disorder [abstract no. NR3-061]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC
28. Panagides J, McIntyre RS, Alphs L, et al. Asenapine in acute mania: a randomized, double-blind, placebo- and olanzapine-controlled trial (ARES 7501004) [abstract no. 720]. Biol Psychiatry 2007 Apr 15; 61 Suppl. 8: 222S-3S
29. Hirschfeld RMA, Panagides J, Alphs L, et al. Asenapine in acute mania: a randomized, double-blind, placebo- and olanzapine-controlled trial (ARES 7501005) [abstract no. NR333]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego (CA)
30. McIntyre R, CohenM, Zhao J, et al. Double-blind extension studies of asenapine in patients with bipolar mania [abstract no. NR4-092]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC
31. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007 Oct; 68 (10): 1492-500
32. Kane JM, Zhao J, Cohen M, et al. Efficacy and safety of asenapine in patients with acute schizophrenia [abstract no. NR4-051]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC
33. Cazorla P, Panagides J, Alphs L, et al. Asenapine versus olanzapine in patients with predominant, persistent negative symptoms of schizophrenia [abstract no. NR4-082]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC
34. Cazorla P, Phiri P, den Hollander W, et al. Long-term treatment with asenapine versus olanzapine in subjects with predominant, persistent negative symptoms of schizophrenia [abstract no. 088]. 47th Annual Meeting of the American College of Neuropsychopharmacology; 2008 Dec 7-11; Scottsdale (AZ)
35. Panagides J, McIntyre RS, Alphs L, et al. Asenapine versus olanzapine in acute mania: a double-blind extension study (ARES 7501006) [abstract no. 721]. Biol Psychiatry 2007 Apr 15; 61 Suppl. 8: 223S
36. van Willigenburg A, Zhao J, Panagides J. Asenapine effects on individual young mania rating scale items in bipolar disorder patients: a pooled analysis [abstract no. NR4-007]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC
37. Cazorla P, Panagides J, Alphs L, et al. Asenapine versus olanzapine in patients with predominant persistent negative symptoms of schizophrenia [abstract no. P-02.26]. Int J Neuropsychopharmacol 2008 Jul; 11 Suppl. 1: 138-9
38. Alphs L, Panagides J, Lancaster S. Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale. Psychopharmacol Bull 2007; 40 (2): 41-53
39. ClinicalTrials.gov. 6-Month extension trial of asenapine with olanzapine in negative symptom patients who completed the first 6-month trial (A7501014) (completed) [online]. Available from URL: http://clinicaltrials.gov/ct2/show/ NCT00174265?term=asenapine+olanzapine+schizophrenia&rank=3 [Accessed 2009 Aug 2]
40. Emsley RA, Schoemaker JH, Vrijland P, et al. Long-term safety of asenapine versus olanzapine in patients with schizophrenia or schizoaffective disorder [abstract no. 323]. 21st Annual US Psychiatric and Mental Health Congress; 2008 Oct 30-Nov 1; San Diego (CA)
41. Preskorn S, Chapel S, Panagides J. Effect of asenapine versus quetiapine and placebo on QTc interval in patients with schizophrenia [abstract no. P.3.c.050]. Eur Neuropsychopharmacol 2007 Oct; 17 Suppl. 4: S453
42. Potkin SG, Kane JM, Emsley RA, et al. Asenapine in schizophrenia: an overview of clinical trials in the Olympia program [abstract no. 78]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC
43. McIntyre R, Panagides J, Alphs L, et al. Treatment of mania in bipolar I disorder: a placebo- and olanzapine-controlled trial of asenapine (ARES 7501005) [abstract no. P.2.e.012]. Eur Neuropsychopharmacol 2007 Oct; 17 Suppl. 4: S383
44. Schering-Plough Corporation. Schering-Plough announces European filing of Sycrest® (asenapine) for the treatment of schizophrenia and bipolar I disorder [media release]. 2009 Jun 2